All In Biotech

Drug Trial Radar · NCT03066804

A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients

A 24-week, Randomized, Double-blind, Multi-center, Parallel LCZ696 on NT-proBNP, Exercise Capacity, Symptoms and Safety Compared to Individualized Medical Management of Comorbidities in Patients With Heart Failure and Preserved Ejection Fraction

Last checked: Nov 19, 2026Latest source record: Oct 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,572 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,572

Actual

Start

Aug 22, 2017

Primary completion

Oct 28, 2019

Study completion Oct 28, 2019

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Feb 28, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to demonstrate the superiority of LCZ696 over individualized medical therapy for comorbidities in reducing N-terminal pro-brain natriuretic peptide (NT-proBNP) and improving exercise capacity and HF symptoms in patients with heart failure with preserved ejection fraction (HFpEF).

Conditions

  • Heart Failure With Preserved Ejection Fraction

Interventions

  • sacubitril/valsartanDrug

    Sacubitril/valsartan is available as 24 mg/26 mg, 49 mg/51 mg, 97 mg/103 mg, respectively in tablet form to be taken orally

  • EnalaprilDrug

    Enalapril is available as 2.5 mg, 5 mg, and 10 mg tablet form to be taken orally

  • ValsartanDrug

    Valsartan is available as 40 mg, 80 mg, 160 mg tablet form to be taken orally

  • Placebo to match sacubitril/valsartanDrug

    Placebo to match LCZ696 50 mg, 100 mg, 200 mg tablet form to be taken orally

  • Placebo to match enalaprilDrug

    Placebo to match enalapril 2.5 mg, 5 mg, 10 mg tablet form to be taken orally

  • Placebo to match valsartanDrug

    Placebo to match valsartan 40 mg, 80 mg, 160 mg tablet form to be taken orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) at Week 12Time frame: Baseline, week 12
  2. Change From Baseline in 6 Minute Walk Distance (6MWD) at Week 24Time frame: Baseline, week 24

Locations

380 sites in 32 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Andalusia, Alabama

  • Novartis Investigative Site

    Mobile, Alabama

  • Novartis Investigative Site

    Beverly Hills, California

  • Novartis Investigative Site

    Long Beach, California

  • Novartis Investigative Site

    Santa Ana, California

  • Novartis Investigative Site

    Sylmar, California

  • Novartis Investigative Site

    Aurora, Colorado

  • Novartis Investigative Site

    Stamford, Connecticut

  • Novartis Investigative Site

    Bradenton, Florida

  • Novartis Investigative Site

    Gainesville, Florida

  • Novartis Investigative Site

    Hollywood, Florida

  • Novartis Investigative Site

    Miami, Florida

  • Novartis Investigative Site

    Port Orange, Florida

  • Novartis Investigative Site

    Thomasville, Georgia

  • Novartis Investigative Site

    Arlington Heights, Illinois

  • Novartis Investigative Site

    Alexandria, Louisiana

  • Novartis Investigative Site

    Chalmette, Louisiana

  • Novartis Investigative Site

    Houma, Louisiana

  • Novartis Investigative Site

    Boston, Massachusetts

  • Novartis Investigative Site

    Lincoln, Nebraska

  • Novartis Investigative Site

    Omaha, Nebraska

  • Novartis Investigative Site

    Rochester, New York

  • Novartis Investigative Site

    Marion, Ohio

  • Novartis Investigative Site

    Corvallis, Oregon

  • Novartis Investigative Site

    Abington, Pennsylvania

  • Novartis Investigative Site

    Sioux Falls, South Dakota

  • Novartis Investigative Site

    Jackson, Tennessee

  • Novartis Investigative Site

    Dallas, Texas

  • Novartis Investigative Site

    Lufkin, Texas

  • Novartis Investigative Site

    Tomball, Texas

  • Novartis Investigative Site

    Falls Church, Virginia

  • Novartis Investigative Site

    Seattle, Washington

  • Novartis Investigative Site

    Buenos Aires, Argentina

  • Novartis Investigative Site

    Córdoba, Argentina

  • Novartis Investigative Site

    Córdoba, Argentina

  • Novartis Investigative Site

    Córdoba, Argentina

  • Novartis Investigative Site

    Córdoba, Argentina

  • Novartis Investigative Site

    Córdoba, Argentina

  • Novartis Investigative Site

    Formosa, Argentina

  • Novartis Investigative Site

    San Luis, Argentina

Showing 40 of 380 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.